PDF(Pubmed)
Abstract：
BACKGROUND: Colorectal cancer (CRC) is one of the most common cancers worldwide. Comprehensive data on the economic burden of CRC at a population-level is critical in informing policymaking, but such data are currently limited in China.
METHODS: From a societal perspective, the economic burden of CRC in 2019 was estimated, including direct medical and nonmedical expenditure, disability, and premature-death-related indirect expenditure. Data on disease burden was taken from the GBD 2019 and analyzed using a prevalence-based approach. The per-person direct expenditure and work loss days were from a multicenter study; the premature-death-related expenditure was estimated using a human capital approach. Projections were conducted in different simulated scenarios. All expenditure data were in Chinese Yuan (CNY) and discounted to 2019.
RESULTS: In 2019, the estimated overall economic burden of CRC in China was CNY170.5 billion (0.189% of the local GDP). The direct expenditure was CNY106.4 billion (62.4% of the total economic burden), 91.4% of which was a direct medical expenditure. The indirect expenditure was CNY64.1 billion, of which 63.7% was related to premature death. The predicted burden would reach CNY560.0 billion in 2030 given constant trends for disease burden; however, it would be alternatively reduced toCONCLUSIONS: The population-level economic burden of CRC in China in 2019 seemed noteworthy, with the direct expenditure accounting for more than half. Without effectively reducing exposure to modifiable factors and expanding screening coverage, the burden would continue increasing.
METHODS: From a societal perspective, the economic burden of CRC in 2019 was estimated, including direct medical and nonmedical expenditure, disability, and premature-death-related indirect expenditure. Data on disease burden was taken from the GBD 2019 and analyzed using a prevalence-based approach. The per-person direct expenditure and work loss days were from a multicenter study; the premature-death-related expenditure was estimated using a human capital approach. Projections were conducted in different simulated scenarios. All expenditure data were in Chinese Yuan (CNY) and discounted to 2019.
RESULTS: In 2019, the estimated overall economic burden of CRC in China was CNY170.5 billion (0.189% of the local GDP). The direct expenditure was CNY106.4 billion (62.4% of the total economic burden), 91.4% of which was a direct medical expenditure. The indirect expenditure was CNY64.1 billion, of which 63.7% was related to premature death. The predicted burden would reach CNY560.0 billion in 2030 given constant trends for disease burden; however, it would be alternatively reduced to
摘要：
背景：结直肠癌（CRC）是全球最常见的癌症之一。关于儿童权利委员会在人口层面的经济负担的全面数据对于为决策提供信息至关重要，但这样的数据目前在中国是有限的。
方法：从社会角度来看，估计了2019年CRC的经济负担，包括直接医疗和非医疗支出，残疾,和过早死亡相关的间接支出。疾病负担数据来自GBD2019，并使用基于患病率的方法进行分析。人均直接支出和工作损失天数来自多中心研究；过早死亡相关支出是使用人力资本方法估算的。在不同的模拟场景中进行了预测。所有支出数据均为人民币（元），并折现至2019年。
结果：2019年，中国CRC的总体经济负担估计为1705亿元人民币（占当地GDP的0.189%）。直接支出1064亿元人民币(占总经济负担的62.4%),其中91.4%为直接医疗支出。间接支出641亿元人民币,其中63.7%与过早死亡有关。鉴于疾病负担的持续趋势，预计到2030年负担将达到5600亿人民币；然而，如果联合国和中国设定的2030年癌症预防和控制目标实现，这一数字将降至5152亿元人民币。
结论：2019年中国CRC的人口经济负担似乎值得注意，直接支出占一半以上。如果没有有效减少对可改变因素的暴露和扩大筛查覆盖面，负担将继续增加。
方法：从社会角度来看，估计了2019年CRC的经济负担，包括直接医疗和非医疗支出，残疾,和过早死亡相关的间接支出。疾病负担数据来自GBD2019，并使用基于患病率的方法进行分析。人均直接支出和工作损失天数来自多中心研究；过早死亡相关支出是使用人力资本方法估算的。在不同的模拟场景中进行了预测。所有支出数据均为人民币（元），并折现至2019年。
结果：2019年，中国CRC的总体经济负担估计为1705亿元人民币（占当地GDP的0.189%）。直接支出1064亿元人民币(占总经济负担的62.4%),其中91.4%为直接医疗支出。间接支出641亿元人民币,其中63.7%与过早死亡有关。鉴于疾病负担的持续趋势，预计到2030年负担将达到5600亿人民币；然而，如果联合国和中国设定的2030年癌症预防和控制目标实现，这一数字将降至5152亿元人民币。
结论：2019年中国CRC的人口经济负担似乎值得注意，直接支出占一半以上。如果没有有效减少对可改变因素的暴露和扩大筛查覆盖面，负担将继续增加。
